glp-1 news november 2025 today Receptor Agonists and vision risk GLP-1 Weight Loss Drug Enforcement

FDA-approved semaglutide formulations (Wegovy*, Ozempic)

The semaglutide diet plan provides a structured framework applicable to tirzepatide users as well

So, it is a bireceptor agonist, product of the above mentioned peptide engineering, created as a single agent possessing activity at more than one pharmacological target

The FDA also raised concerns about contamination, incorrect dosages, unapproved or harmful ingredients, and counterfeit components in compounded GLP-1s

Additional semaglutide risks include pancreatitis, gallbladder disease, acute kidney injury, and diabetic retinopathy complications in patients with diabetes

Their activation leads to inhibition of T cell differentiation, downregulation of neutrophil superoxide production, as well as an inhibition of pro-inflammatory cytokine production [76]